| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2002;124:285-292
© 2002 The American Association for Thoracic Surgery
General Thoracic Surgery (GTS) |
From the Clinical Laboratory Divisiona and Thoracic Surgery Division,b National Cancer Center Hospital, and Pathology Division, National Cancer Center Research Institute,c Tokyo, Japan.
Supported in part by Grants-in-Aid for Cancer Research (11-19 and 12-5) from the Ministry of Health, Labor, and Welfare of Japan.
Received for publication Sept 5, 2001. Revisions requested Oct 19, 2001; revisions received Nov 26, 2001. Accepted for publication Dec 20, 2001. Address for reprints: Yoshihiro Matsuno, MD, Clinical Laboratory Division, National Cancer Center Hospital, 1-1, Tsukiji 5 chome, Chuo-ku, Tokyo, 104-0045, Japan (E-mail: ymatsuno{at}ncc.go.jp).
Objective: Large cell neuroendocrine carcinoma of the lung is a newly recognized clinicopathologic entity. The clinical characteristics and optimal treatment of patients with large cell carcinomas are not yet established. The aim of this study was to define the clinicopathologic characteristics of large cell neuroendocrine carcinoma.
Methods: The histologic characteristics of the patients receiving an initial diagnosis of poorly differentiated non-small cell lung carcinoma (n = 484), small cell carcinoma (n = 55), carcinoid (n = 31), and large cell neuroendocrine carcinoma (n = 12) were retrospectively reviewed according to World Health Organization criteria. Immunohistochemistry was performed to confirm the neuroendocrine phenotype. The outcomes and other clinical characteristics of those patients with large cell neuroendocrine carcinoma were retrospectively analyzed and compared with those of patients with poorly differentiated carcinoma of other histologic types.
Results: A total of 87 patients were given a diagnosis of large cell neuroendocrine carcinoma after the histologic review. These patients comprised 3.1% of all patients undergoing resection for primary lung cancer during the same period. The overall 5-year survival was 57%. The 5-year survivals of patients with stage I, II, III, and IV disease were 67%, 75%, 45%, and 0%, respectively. There was no statistically significant difference between the overall survival of patients with large cell neuroendocrine carcinoma and those with other non-small cell lung cancers. There was a significant difference between the survival of patients with stage I large cell neuroendocrine carcinoma and that of patients with the same stage of other non-small cell lung carcinomas. The site of the first documented recurrence was locoregional in 12 patients (34%), distant metastases in 20 patients (57%), and both simultaneously in 3 patients. Locoregional lymph node recurrences were observed frequently. More than 80% of recurrences were found within 1 year after the operation.
Conclusion: In terms of prognosis, large cell neuroendocrine carcinoma is distinctly different from other non-small cell lung cancers. The prognosis of large cell neuroendocrine carcinoma was poor, even for early stage disease; the prognosis of the stage I disease of large cell neuroendocrine carcinoma was poorer than that of the same stage of other non-small cell lung cancers. Because of its aggressive clinical behavior and poor prognosis, large cell neuroendocrine carcinoma should be recognized as one of the poorest prognostic subgroups among primary lung cancers, and therefore novel therapeutic approaches should be established.
This article has been cited by other articles:
|
|
 |
|
  A. Iyoda, K. Hiroshima, Y. Nakatani, and T. Fujisawa Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujiwara, I. Sekine, K. Tsuta, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, K. Yamada, and T. Tamura Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung Jpn. J. Clin. Oncol., July 24, 2007; (2007) hym053v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Iyoda, K. Hiroshima, Y. Moriya, Y. Takiguchi, Y. Sekine, K. Shibuya, T. Iizasa, H. Kimura, Y. Nakatani, and T. Fujisawa Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma Ann. Thorac. Surg., November 1, 2006; 82(5): 1802 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iyoda, K. Hiroshima, Y. Moriya, Y. Sekine, K. Shibuya, T. Iizasa, Y. Nakatani, and T. Fujisawa Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 312 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Asamura, T. Kameya, Y. Matsuno, M. Noguchi, H. Tada, Y. Ishikawa, T. Yokose, S.-X. Jiang, T. Inoue, K. Nakagawa, et al. Neuroendocrine Neoplasms of the Lung: A Prognostic Spectrum J. Clin. Oncol., January 1, 2006; 24(1): 70 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chong, K. S. Lee, M. J. Chung, J. Han, O J. Kwon, and T. S. Kim Neuroendocrine Tumors of the Lung: Clinical, Pathologic, and Imaging Findings RadioGraphics, January 1, 2006; 26(1): 41 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Shin, S. M. Kang, Y. S. Kim, D. H. Shin, J. Chang, S. K. Kim, and S. K. Kim Identification of Tumor Suppressor Loci on the Long Arm of Chromosome 5 in Pulmonary Large Cell Neuroendocrine Carcinoma Chest, October 1, 2005; 128(4): 2999 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Battafarano, F. G. Fernandez, J. Ritter, B. F. Meyers, T. J. Guthrie, J. D. Cooper, and G. A. Patterson Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Filosso, E. Ruffini, A. Oliaro, O. Rena, C. Casadio, M. Mancuso, D. Turello, R. C. Cristofori, and G. Maggi Large-cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 819 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Paci, A. Cavazza, V. Annessi, I. Putrino, G. Ferrari, S. De Franco, and G. Sgarbi Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study Ann. Thorac. Surg., April 1, 2004; 77(4): 1163 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Doddoli, F. Barlesi, B. Chetaille, L. Garbe, P. Thomas, R. Giudicelli, and P. Fuentes Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery Ann. Thorac. Surg., April 1, 2004; 77(4): 1168 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Casali, A. Stefani, G. Rossi, M. Migaldi, S. Bettelli, A. Parise, and U. Morandi The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung Ann. Thorac. Surg., January 1, 2004; 77(1): 247 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oshiro, M. Kusumoto, Y. Matsuno, H. Asamura, R. Tsuchiya, H. Terasaki, H. Takei, A. Maeshima, S. Murayama, and N. Moriyama CT Findings of Surgically Resected Large Cell Neuroendocrine Carcinoma of the Lung in 38 Patients Am. J. Roentgenol., January 1, 2004; 182(1): 87 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Borczuk, L. Gorenstein, K. L. Walter, A. A. Assaad, L. Wang, and C. A. Powell Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways Am. J. Pathol., November 1, 2003; 163(5): 1949 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takei, H. Asamura, and Y. Matsunomo Reply J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1183 - 1184. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Filosso Large cell neuroendocrine carcinoma of the lung: What we have to do J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1182 - 1183. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hage, K. Seldenrijk, P. de Bruin, H. van Swieten, and J. van den Bosch Pulmonary large-cell neuroendocrine carcinoma (LCNEC) Eur. J. Cardiothorac. Surg., April 1, 2003; 23(4): 457 - 460. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
